Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 11/20 | 0.59 |
| ▸ | DYRK2 | Q92630 | 11/20 | 0.59 |
| ▸ | DYRK1B | Q9Y463 | 10/20 | 0.59 |
| ▸ | CDK5 | Q00535 | 9/20 | 0.59 |
| ▸ | CDK5R1 | Q15078 | 9/20 | 0.59 |
| ▸ | DYRK3 | O43781 | 9/20 | 0.59 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.59 |
| ▸ | CDK2 | P24941 | 7/20 | 0.59 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.51 |
| ▸ | CDK9 | P50750 | 6/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.43 |
| ▸ | FYN | P06241 | 5/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9902768 | 0.87 | DYRK1A (0.50) | DYRK1ADYRK2DYRK1BCDK5CDK5R1 | |
| SCHEMBL9902267 | 0.82 | DYRK1A (0.58) | DYRK1ADYRK2DYRK1BCDK5CDK5R1 | |
| SCHEMBL9903599 | 0.78 | DYRK1A (0.48) | DYRK1ADYRK2DYRK1BCDK5CDK5R1 | |
| SCHEMBL9902779 | 0.77 | ALK (0.43) | DYRK1ADYRK2DYRK1BCDK5CDK5R1 | |
| SCHEMBL16371015 | 0.74 | DYRK1A (0.56) | DYRK1ADYRK2DYRK1BCDK5CDK5R1 | |
| SCHEMBL13234222 | 0.74 | DYRK1A (0.58) | DYRK1ADYRK2DYRK1BCDK5CDK5R1 | |
| SCHEMBL13234221 | 0.73 | FYN (0.68) | DYRK1ADYRK2DYRK1BCDK5CDK5R1 | |
| SCHEMBL3043884 | 0.72 | FYN (0.67) | DYRK1ADYRK2DYRK1BCDK5CDK5R1 | |
| SCHEMBL3513641 | 0.72 | FYN (0.74) | FYN | |
| SCHEMBL13234223 | 0.72 | FYN (0.61) | DYRK1ADYRK2DYRK1BCDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133200-B2 | Imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives as JAK inhibitors | ALMIRALL, S.A. (ES) | 2015-09-15 | — | — | US | disclosed |
| US-20130309200-A1 | IMIDAZO [1,2-B] PYRIDAZINE AND IMIDAZO [4,5-B] PYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-11-21 | — | — | US | disclosed |
| EP-2463289-A1 | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors | Almirall, S.A. (ES) | 2012-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130309200-A1 | IMIDAZO [1,2-B] PYRIDAZINE AND IMIDAZO [4,5-B] PYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | DYRK1A 595/4885DYRK2 356/4885DYRK1B 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.